1567 related articles for article (PubMed ID: 26086041)
21. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
[TBL] [Abstract][Full Text] [Related]
22. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study.
Mouchawar J; Korch C; Byers T; Pitts TM; Li E; McCredie MR; Giles GG; Hopper JL; Southey MC
Cancer Res; 2010 Jun; 70(12):4795-800. PubMed ID: 20501846
[TBL] [Abstract][Full Text] [Related]
23. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
24. Low frequency of AXIN2 mutations and high frequency of MUTYH mutations in patients with multiple polyposis.
Lejeune S; Guillemot F; Triboulet JP; Cattan S; Mouton C; ; Porchet N; Manouvrier S; Buisine MP
Hum Mutat; 2006 Oct; 27(10):1064. PubMed ID: 16941501
[TBL] [Abstract][Full Text] [Related]
25. Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.
Nyiraneza C; Jouret-Mourin A; Kartheuser A; Camby P; Plomteux O; Detry R; Dahan K; Sempoux C
Hum Pathol; 2011 Dec; 42(12):1897-910. PubMed ID: 21665242
[TBL] [Abstract][Full Text] [Related]
26. Germ line BAX alterations are infrequent in Li-Fraumeni syndrome.
Barlow JW; Mous M; Wiley JC; Varley JM; Lozano G; Strong LC; Malkin D
Cancer Epidemiol Biomarkers Prev; 2004 Aug; 13(8):1403-6. PubMed ID: 15298965
[TBL] [Abstract][Full Text] [Related]
27. High frequency of germline p53 mutations in childhood adrenocortical cancer.
Wagner J; Portwine C; Rabin K; Leclerc JM; Narod SA; Malkin D
J Natl Cancer Inst; 1994 Nov; 86(22):1707-10. PubMed ID: 7966399
[TBL] [Abstract][Full Text] [Related]
28.
Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
[TBL] [Abstract][Full Text] [Related]
29. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family.
van Hest LP; Ruijs MW; Wagner A; van der Meer CA; Verhoef S; van't Veer LJ; Meijers-Heijboer H
Fam Cancer; 2007; 6(3):311-6. PubMed ID: 17318340
[TBL] [Abstract][Full Text] [Related]
30. Gastric cancer in individuals with Li-Fraumeni syndrome.
Masciari S; Dewanwala A; Stoffel EM; Lauwers GY; Zheng H; Achatz MI; Riegert-Johnson D; Foretova L; Silva EM; Digianni L; Verselis SJ; Schneider K; Li FP; Fraumeni J; Garber JE; Syngal S
Genet Med; 2011 Jul; 13(7):651-7. PubMed ID: 21552135
[TBL] [Abstract][Full Text] [Related]
31. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
32. Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients.
Zerdoumi Y; Aury-Landas J; Bonaïti-Pellié C; Derambure C; Sesboüé R; Renaux-Petel M; Frebourg T; Bougeard G; Flaman JM
Hum Mutat; 2013 Mar; 34(3):453-61. PubMed ID: 23172776
[TBL] [Abstract][Full Text] [Related]
33. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
[TBL] [Abstract][Full Text] [Related]
34. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
Fortuno C; James PA; Spurdle AB
Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
[TBL] [Abstract][Full Text] [Related]
35. TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma.
Andrade RC; de Lima MAFD; de Faria PAS; Vargas FR
Fam Cancer; 2018 Jan; 17(1):119-122. PubMed ID: 28477317
[TBL] [Abstract][Full Text] [Related]
36. The TP53 gene promoter is not methylated in families suggestive of Li-Fraumeni syndrome with no germline TP53 mutations.
Finkova A; Vazna A; Hrachovina O; Bendova S; Prochazkova K; Sedlacek Z
Cancer Genet Cytogenet; 2009 Aug; 193(1):63-6. PubMed ID: 19602465
[TBL] [Abstract][Full Text] [Related]
37. TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis.
Marcel V; Palmero EI; Falagan-Lotsch P; Martel-Planche G; Ashton-Prolla P; Olivier M; Brentani RR; Hainaut P; Achatz MI
J Med Genet; 2009 Nov; 46(11):766-72. PubMed ID: 19542078
[TBL] [Abstract][Full Text] [Related]
38. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
[TBL] [Abstract][Full Text] [Related]
39. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
40. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
